The P2X7 receptor antagonist Brilliant Blue G reduces serum human interferon-γ in a humanized mouse model of graft-versus-host disease
Open Access
- 24 July 2017
- journal article
- Published by Oxford University Press (OUP) in Clinical and Experimental Immunology
- Vol. 190 (1) , 79-95
Abstract
Summary: Graft-versus-host disease (GVHD) remains a major problem after allogeneic haematopoietic stem cell transplantation, a curative therapy for haematological malignancies. Previous studies have demonstrated a role for the adenosine triphosphate (ATP)-gated P2X7 receptor channel in allogeneic mouse models of GVHD. In this study, injection of human peripheral blood mononuclear cells (PBMCs) into immunodeficient non-obese diabetic-severe combined immunodeficiency-interleukin (NOD-SCID-IL)-2Rγnull (NSG) mice established a humanized mouse model of GVHD. This model was used to study the effect of P2X7 blockade in this disease. From five weeks post-PBMC injection, humanized mice exhibited clinical signs and histopathology characteristic of GVHD. The P2X7 antagonist, Brilliant Blue G (BBG), blocked ATP-induced cation uptake into both murine and human cells in vitro. Injection of BBG (50 mg/kg) into NSG mice did not affect engraftment of human leucocytes (predominantly T cells), or the clinical score and survival of mice. In contrast, BBG injection reduced circulating human interferon (IFN)-γ significantly, which was produced by human CD4+ and CD8+ T cells. BBG also reduced human T cell infiltration and apoptosis in target organs of GVHD. In conclusion, the P2X7 antagonist BBG reduced circulating IFN-γ in a humanized mouse model of GVHD supporting a potential role for P2X7 to alter the pathology of this disease in humans.Keywords
Funding Information
- Illawarra Health and Medical Research Institute
- Centre for Medical and Molecular Biosciences
- AMP Foundation Australia
This publication has 49 references indexed in Scilit:
- P2X7 Receptor Activation Induces Reactive Oxygen Species Formation and Cell Death in Murine EOC13 MicrogliaMediators of Inflammation, 2013
- Risk factors for acute GVHD and survival after hematopoietic cell transplantationBlood, 2012
- Association between P2X7 Receptor Polymorphisms and Bone Status in MiceJournal of Osteoporosis, 2012
- Expression, assembly and function of novel C‐terminal truncated variants of the mouse P2X7 receptor: re‐evaluation of P2X7 knockoutsBritish Journal of Pharmacology, 2011
- Reciprocal differentiation and tissue-specific pathogenesis of Th1, Th2, and Th17 cells in graft-versus-host diseaseBlood, 2009
- Systemic administration of an antagonist of the ATP-sensitive receptor P2X7 improves recovery after spinal cord injuryProceedings of the National Academy of Sciences, 2009
- Blockade of interleukin-6 signaling augments regulatory T-cell reconstitution and attenuates the severity of graft-versus-host diseaseBlood, 2009
- Graft-versus-host diseaseThe Lancet, 2009
- Human peripheral blood leucocyte non-obese diabetic-severe combined immunodeficiency interleukin-2 receptor gamma chain gene mouse model of xenogeneic graft-versus-host-like disease and the role of host major histocompatibility complexClinical and Experimental Immunology, 2009
- Interleukins 1β and 6 but not transforming growth factor-β are essential for the differentiation of interleukin 17–producing human T helper cellsNature Immunology, 2007